Robert Driscoll
Stock Analyst at Wedbush
(1.84)
# 3,149
Out of 4,896 analysts
161
Total ratings
29.58%
Success rate
-8.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Reiterates: Outperform | $36 | $6.28 | +473.25% | 9 | Jun 20, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.33 | +200.75% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $1.19 | +404.20% | 3 | May 9, 2025 | |
| RVMD Revolution Medicines | Reiterates: Outperform | $67 | $38.04 | +76.13% | 5 | Apr 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $5.16 | +229.46% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $7.79 | +54.04% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $6.79 | +371.28% | 6 | Feb 26, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $22.46 | +131.52% | 9 | Dec 17, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $10.32 | +171.32% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $2.87 | +457.49% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $9.33 | +221.54% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $1.36 | +1,517.65% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $8.27 | +516.69% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.75 | +567.11% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $7.71 | +366.93% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.73 | +535.84% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $5.40 | +140.74% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $5.93 | +119.22% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $25.19 | +193.77% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.70 | +196.30% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.32 | +430.30% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $2.42 | +230.58% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.38 | +2,022.58% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $10.97 | +374.02% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.17 | +26.18% | 4 | May 19, 2020 |
Kura Oncology
Jun 20, 2025
Reiterates: Outperform
Price Target: $36
Current: $6.28
Upside: +473.25%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.33
Upside: +200.75%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $1.19
Upside: +404.20%
Revolution Medicines
Apr 28, 2025
Reiterates: Outperform
Price Target: $67
Current: $38.04
Upside: +76.13%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $5.16
Upside: +229.46%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $7.79
Upside: +54.04%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $6.79
Upside: +371.28%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $22.46
Upside: +131.52%
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $10.32
Upside: +171.32%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.87
Upside: +457.49%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $9.33
Upside: +221.54%
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.36
Upside: +1,517.65%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $8.27
Upside: +516.69%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.75
Upside: +567.11%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $7.71
Upside: +366.93%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.73
Upside: +535.84%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.40
Upside: +140.74%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $5.93
Upside: +119.22%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $25.19
Upside: +193.77%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.70
Upside: +196.30%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.32
Upside: +430.30%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $2.42
Upside: +230.58%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.38
Upside: +2,022.58%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $10.97
Upside: +374.02%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.17
Upside: +26.18%